Autophagy is a catabolic membrane-trafficking process that leads to sequestration and degradation of intracellular material within lysosomes. It is executed at basal levels in every cell and promotes cellular homeostasis by regulating organelle and protein turnover. In response to various forms of cellular stress, however, the levels and cargoes of autophagy can be modulated. In nutrient-deprived states, for example, autophagy can be activated to degrade cargoes for cell-autonomous energy production to promote cell survival. In other contexts, in contrast, autophagy has been shown to contribute to cell death. Given these dual effects in regulating cell viability, it is no surprise that autophagy has implications in both the genesis and treatment of malignant disease. In this review, we provide a comprehensive appraisal of the way in which oncogenes and tumour suppressor genes regulate autophagy. In addition, we address the current evidence from human cancer and animal models that has aided our understanding of the role of autophagy in tumour progression. Finally, the potential for targeting autophagy therapeutically is discussed in light of the functions of autophagy at different stages of tumour progression and in normal tissues.
Paradoxically, however, although a clear role in cell survival undoubtedly exists, evidence also points to a tumour-suppressive role: downregulation of several autophagy genes occurs in human cancer, mouse models where critical autophagy regulators have been deleted support a role for autophagy in tumour suppression, and autophagy has been implicated in cell death and oncogene-induced senescence ( Refs 4, 5, 6, 7) . A conundrum currently exists, therefore, as to the role of autophagy in cancer, with perhaps different roles being played at different stages and in different tumour types (Ref. 8) . Understanding this issue in great detail is seemingly critical if we are to consider targeting autophagy -either positively or negativelyfor therapeutic gain.
Mechanisms of autophagy
Autophagy when translated from the Greek literally means 'self-eating', and comprises a multistep process of sequestration and subsequent degradation of intracellular material within specialised compartments (Refs 9, 10). Autophagy is orchestrated by a subset of genes that were originally identified in yeast and are called autophagy-related genes (ATG), many of which have mammalian orthologues (Refs 10, 11). Autophagy can be divided into different stages that ultimately result in lysosomal breakdown of cytoplasmatic material: initiation; autophagosome formation (nucleation, elongation and completion); and maturation and degradation. These are discussed in detail below and depicted in Figure 1 .
Initiation
Initiation in mammalian cells starts with the activation of a serine/threonine kinase complex that contains ULK1/2 (orthologues of the yeast protein Atg1), ATG13 and FIP200 (RB1CC1) This complex transfers signals from the nutrient-sensing mTOR kinase (MTOR; mammalian/mechanistic target of rapamycin) to initiate autophagy ( Refs 12, 13, 14, 15) . Inhibition of mTOR-induced phosphorylation of ULK and ATG13 liberates the kinase activity of ULK, which subsequently phosphorylates itself, ATG13 and FIP200. The ULK complex then accumulates at the initiating focus of vesicle formation: the isolation membrane or phagophore ( Refs 13, 14, 15) .
Autophagosome formation
Vesicle nucleation -the further development of the isolation membrane/phagophore -critically depends on the activity of the class III phosphoinositide 3-kinase (PI3K-III) hVps34 (PIK3C3; the orthologue of yeast Vps34) and its formation of a complex with Beclin 1 (yeast Atg6) and p150/hVps35 (PIK3R4; yeast Vps15) (Refs 16, 17) .
Vesicle elongation and completion from the isolation membrane/phagophore to a nascent autophagosome and the completed, closed autophagosome is mediated by two ubiquitinlike conjugation systems: the ATG12 and ATG8 conjugation systems (Ref. 18 ). The ubiquitin-like ATG12 is activated by ATG7 and then temporarily binds to the E2-like enzyme ATG10 before being transferred to ATG5. ATG5 further reacts with ATG16 to form a multimeric complex of ATG12 -ATG5 -ATG16 ( Refs 19, 20) . In mammalian cells, several orthologues of yeast Atg8 have been identified: MAP1LC3 (LC3), GABARAPL2 (GATE16), GABARAP and GABARAPL1 (ATG8L). They are subjected to modification steps similar to those of their yeast counterpart. The processing of the autophagosome marker LC3 has been investigated most thoroughly, and its stepwise conversion from a cytosolic to a membranebound form is exploited for the experimental measurement of autophagy (Ref. 21) . LC3 is synthesised as a precursor protein proLC3 and is immediately processed to LC3-I by ATG4 through cleavage of the C-terminal amino acid. LC3 maturation completes with the reversible conjugation of LC3-I to phosphatidylethanolamine (PE) at the C-terminus by ATG3 and ATG7 to form LC3-II on the surface of autophagosomes (Refs 19, 20) .
Both the ATG12 -ATG5 -ATG16 complex and LC3-II are essential for autophagy. The ATG12 -ATG5 -ATG16 complex is required for targeting of LC3 to the autophagosomal membrane and accelerated conjugation of LC3 to PE. Atg8, the yeast counterpart of LC3, controls the expansion of the phagophore and the amount of Atg8 directly correlates to the size of the autophagosomes ( Refs 19, 22) . The different stages of autophagosome formation are intertwined and difficult to separate. Therefore the assignment of the different ATGs to corresponding stages and autophagic vesicles is to some degree academic. Following an initiating event, ATGs orchestrate the formation of autophagic vesicles from the phagophore/isolation membrane to the autophagosome and finally the autolysosome. The ULK-ATG13-FIP200 and the Beclin-1 -hVps34-p150 complexes mediate early nucleation events, whereas the two ubiquitin-like conjugation systems (ATG5-ATG12 and LC3-II) direct vesicle elongation and autophagosome formation. Cellular material is finally sequestered within the autophagosome and thereby separated from the cytoplasm. Intracellular material is degraded in autolysosomes, which result from a fusion of lysosomes with autophagosomes. Importantly, autophagy is the complete process from initiation to degradation and not just the accumulation of autophagosomes. Abbreviations: ATG, autophagy-related protein; Beclin 1, coiled-coil myosin-like Bcl-2-interacting protein; FIP200, 200 kDa FAK family kinase-interacting protein; hVps34, human vacuolar protein sorting-associated protein 34; LC3, (microtubule-associated protein) light chain 3; mTOR, mammalian/mechanistic target of rapamycin; p150, regulatory subunit of hVps34; P, phosphorylation; ULK1/2, unc-51-like kinase 1/2.
Mechanisms of autophagy
Expert
Maturation and degradation
The maturation process encompasses the fusion of autophagosomes with lysosomes to form the end-stage vesicle of autophagy: the autolysosome. Currently it is unclear how autophagy is to be interpreted in the context of cancer. As outlined above, the unsolved paradox is that on the one hand its cytoprotective traits could clearly promote survival of both cancer and normal cells (Refs 1, 3), whereas on the other hand autophagy might suppress tumour growth through its connection to cell death, senescence and oxidative stress (Refs 6, 7, 25, 26, 27, 28) . The genetic evidence that autophagy and cancer are linked is overwhelming (Refs 11, 29, 30) . We detail here in a piecemeal fashion the data that have accumulated from humans and mouse models about the function of ATGs, their direct binding partners and their roles in either protecting against or promoting cancer.
Beclin 1
Beclin 1 (BECN1) is a critical autophagyregulating gene and provided the first human genetic link between autophagy and cancer. It is monoallelically deleted in 50% of human breast, ovarian and prostate cancers and expressed only at low levels in brain tumours (Refs 31, 32, 33 
ATG5 and ATG7
ATG5 and ATG7 are two other critical autophagy regulators that have been deleted in experimental animal models. Unlike complete deletion of Becn1, deficiency in ATG5 or ATG7 is not embryonically lethal and mice are born normal without any apparent abnormalities; however, both Atg5 2/2 and Atg7 2/2 mice die within 24 h after birth, presumably as a result of an inability to compensate the neonatal starvation period that occurs after being cut off from the maternal circulation, when autophagy is normally transiently upregulated (Refs 3, 36). Mice hemizygous for either Atg5 or Atg7 are born viable and develop normally. In contrast to Becn1-hemizygous animals, however, they do not develop tumours (Refs 3, 36). Intercrossing tumour-prone mice to recently developed conditional knockout mice for Atg5 and Atg7 (Refs 36, 37) will seemingly be required for the spatial and temporal dissection of the contribution of these genes to cancer development.
ATG4
Yeast Atg4 has four mammalian orthologues, of which ATG4C (autophagin-3) is most widely 
Summary
In summary, the available data from humans and mouse models where ATGs or their direct positive modulators are lost or expressed at low levels point towards a tumour-suppressive role of autophagy. It is important to keep in mind, however, that in all the above mouse models autophagy inhibition involved deletion of the gene in the target cells embryonically. As a result, all the pathologies observed arose from cells that had always had impaired autophagy. These experiments thus do not clarify the role of acute autophagy loss at a later developmental stage, for instance in an established tumour, a scenario that likely occurs in vivo. In order to address this important question, further analysis is therefore required of conditional autophagy-deficient animals, by using inducible Cre recombinases so that gene deletion can be achieved in the adult animal in a tissue-and tumour-specific manner.
Genetic regulation of autophagy in cancer
As indicated above, the control of autophagy is multifactorial and incompletely understood, but there is an emerging trend that tumour suppressors induce autophagy whereas oncogenes have the opposite effect (Refs 5, 42). Many oncogenic and tumour-suppressive effects impact ultimately on mTOR and complexes of Beclin 1 and hVps34 (Beclin-1 -hVps34), which are central to autophagy regulation in many contexts (Ref. 43 ). These complexes therefore merit prior discussion in order to fully understand the control of autophagy by classic oncogenes and tumour suppressors (Fig. 2 ).
mTOR is a gateway for the control of autophagy
The serine/threonine kinase mTOR is a focal point for the action of many oncogenic and metabolic events as well as the control of autophagy. 
Bcl-X L Beclin-1-hVps34 complex The Beclin-1 -hVps34 -p150 core complex is complemented by different regulatory proteins that bind to Beclin 1 through domains other than BH3 and define its role in autophagy. To date, three different forms of the complex have been identified, all of which have different functions. They contain either ATG14/ BARKOR (Beclin-1-associated autophagyrelated key regulator) or UVRAG alone, or both UVRAG and Rubicon (RUN domain and cysteine-rich domain containing). It has been proposed that the ATG14/BARKORcontaining complex targets hVps34 activity towards the isolation membrane and thus functions in autophagosome formation, and that the UVRAG-containing complex promotes autophagosome and endosome maturation (Ref. 54 ). ATG14/BARKOR positively regulates autophagy, promotes translocation of Beclin 1 to autophagosomes and competes with UVRAG for the same binding site on Beclin 1 (Ref. 55) . By contrast, the UVRAG-and Rubiconcontaining complex suppresses autophagosome and endosome maturation (Refs 56, 57). Knockdown of ATG14/BARKOR inhibits autophagy whereas knockdown of Rubicon has the opposite effect, providing further evidence that Beclin 1 has multiple roles in autophagy through the formation of complexes with opposing actions (Fig.  3) . Although perturbation of Beclin 1 clearly has implications for cancer, a role for ATG14/BARKOR in cancer has not yet been defined. AMBRA1 is another protein that binds the Beclin-1 -hVps34 complex, with a role in the regulation of autophagy in neuronal development (Ref. 58) . However, as with ATG14/BARKOR, its role in autophagy regulation has also not yet been extended to cancer. figure. ) A multitude of pathways that are commonly deregulated in cancer control autophagy via its master switches mTOR and the complex of Beclin 1 and hVps34 (Beclin-1-hVps34). Hypoxia and limited nutrient supply are frequently encountered in tumours and lead to activation of autophagy via engagement of the same networks. Autophagy-inducing regulators are depicted in green, inhibiting regulators in red, and those that have a dual effect on autophagy in yellow. The asterisk indicates that the mechanism of Rasinduced upregulation of autophagy in senescence remains to be fully elucidated. Abbreviations: AKT, RACalpha serine/threonine-protein kinase; AMPK, AMP-activated protein kinase; ARHI, aplasia Ras homologue member I (also known as DIRAS3 for DIRAS family, GTP-binding RAS-like 3); BAD, Bcl-2-associated antagonist of cell death; Bcl-2, B-cell CLL/lymphoma 2 (apoptosis regulator); Bcl-X L , B-cell lymphoma-extra large; Beclin 1, coiled-coil myosin-like Bcl-2-interacting protein; BIF1, endophilin B1; BNIP3(L), BCL2/ adenovirus E1B 19 kDa protein-interacting protein 3-(like); DAPK, death-associated protein kinase; DRAM1, damage-regulated autophagy modulator protein 1; ERK, extracellular-signal-regulated kinase; HIF1, hypoxia-inducible factor 1; MAP1B, microtubule-associated protein 1B; Mcl-1, induced myeloid leukaemia cell differentiation protein; mTORC1, mTOR complex 1; p53, cellular tumour antigen p53; p73, tumour protein p73; PDGFR, platelet-derived growth factors receptor; PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K-I, phosphoinositide 3-kinase class I; PTEN, phosphatase and tensin homologue; Ras, GTPase Ras; RTK, receptor tyrosine kinase; RHEB, Ras homologue enriched in brain; STK11, serine/ threonine-protein kinase 11 (also known as LKB1); TSC1, hamartin, tuberous sclerosis 1 protein; TSC2, tuberin, tuberous sclerosis 2 protein; UVRAG, UV-radiation-resistance-associated gene.
Oncogenes and tumour suppressors
As outlined above, many oncogenes and tumour suppressors exert opposing effects on autophagy, often through direct or indirect regulation of mTOR and Beclin-1 -hVps34, but also through currently unknown mechanisms. In the following examples we outline the reported effects of tumour-associated proteins on both autophagy and apoptosis.
PI3K-I
PI3K-I (class I phosphoinositide 3-kinase) is a lipid kinase activated via receptor tyrosine 
Ras-MEK-ERK
The Ras -MEK -ERK pathway is deregulated in many cancers and has a central role in mTOR activation independent of AKT. p53 (TP53) is a major tumour suppressor, being mutated or lost in 50% of all human cancers (Ref. 75) . In response to various forms of cellular stress, p53 becomes activated, leading to multiple phenotypic effects including induction of cell-cycle arrest and cell death (Ref. 76 ). Since p53 has been shown to respond to, and also to modulate, metabolic stress, it is perhaps no surprise that p53 has also been found to regulate autophagy (Refs 77, 78, 79).
The way in which p53 regulates autophagy, however, appears to be dependent on context. When elevated by cellular stress, p53 accumulates in the nucleus and activates target genes that mediate its tumour-suppressive effects. One of these genes, DRAM1 (damageregulated-autophagy modulator), encodes a phylogenetically conserved lysosomal protein that promotes autophagy (Refs 77, 80, 81) . Interestingly, DRAM1 was also found to be required for p53-induced programmed cell death, although the mechanism underlying the interplay between DRAM1, autophagy and apoptosis is yet to be determined (Ref. 77 ). p73 (TP73), a closely related protein to p53, has also been shown to modulate DRAM1 and autophagy, although autophagy induced by p73 was found to be independent of DRAM1 (Ref. 82) . Since this points to other target genes of p53/p73 being involved in autophagy regulation, it is interesting to note that sestrin 2 (SESN2) has also been linked to both p53 and p73 (Refs 83, 84). In an independent study, sestrins have been shown to modulate mTOR through AMPK (Ref. 85) . A link has now also been reported between p53, sestrin 2 and autophagy (Ref. 86) , although the role of sestrin 2 in p73-driven autophagy is yet to be explored.
In the absence of cellular stress, basal levels of p53 have, in contrast, been shown to inhibit autophagy. This effect, however, does not involve gene activation and occurs through a cytoplasmic mechanism at the endoplasmic reticulum (Ref. 79) . Pharmacological inhibition or genetic ablation of p53, both in vitro and in vivo, was shown to induce autophagy. Although the induction and inhibition of autophagy by p53 are mechanistically distinct and therefore seemingly separable, it would be interesting to study the balance of these two effects when both are active -are they opposing or mutually exclusive? In this regard, it is interesting to note that certain tumourderived mutants of p53 can inhibit autophagy through the cytoplasmic mechanism, but they do not cause the activation of DRAM1 or sestrin 2 that would be required for the induction of autophagy (Ref. 87 ). In tumours with mutant p53, therefore, it would be conceivable that autophagy would be reduced through both lack of induction as well as enforced inhibition.
ARF
ARF ['alternative reading frame' of the CDKN2A (INK4A) locus] is a bona fide tumour suppressor that is known to induce p53 levels following oncogenic stress and as a result has been shown to induce p53-dependent autophagy and thereby to enhance cell death. ARF-induced autophagy might therefore contribute to its tumour-suppressive function (Ref. 88) . ARF can also induce autophagy in the absence of p53, probably through interaction with Bcl-X L which normally inhibits the Beclin-1 -hVps34 complex (Ref. 89) . A smaller truncated form of ARF, smARF (resulting from initiation from an alternative internal methionine), has also recently been found to modulate autophagy in a p53-independent manner. In this context, smARF is considered to induce autophagy at mitochondria and causes induction of a cell death dependent on autophagy genes (Ref. 90) .
Others
In addition to the tumour suppressors and oncogenes discussed above, which have been shown to have an active role in autophagy regulation, several other tumour-associated factors could be postulated to modulate autophagy given their connection to pathways that have been previously implicated in autophagy regulation. As an element of speculation is involved, an exhaustive list of such factors could be generated; we feel, however, that the factors listed below are worthy of discussion even if further studies are required to clarify a connection to autophagy regulation and the extent to which this may be important for the role of the factor in tumour development.
NF1
NF1 (neurofibromin) is a tumour suppressor that antagonises Ras, and loss-of-function mutations of NF1 are associated with the familial neurofibromatosis type 1 tumour syndrome (Recklinghausen disease), which is characterised by development of benign tumours of the nervous system, as well as a more general predisposition to cancer (Ref. 61) . Complicating understanding of the role of NF1 is the fact that acute loss of NF1 in human diploid fibroblasts leads to a transient upregulation of Ras, but ultimately suppresses the Ras -PI3K-I pathway and leads to expert reviews 
Summary
In summary, the mTOR and Beclin-1 -hVps34 complexes are targeted by a multitude of different oncogenes and tumour suppressors, which thereby regulate autophagy. New players are constantly being identified and new links are being made, making the regulation of autophagy in cancer incredibly complex.
Mechanisms for how loss of autophagy contributes to tumourigenesis
It is currently unclear how loss of autophagy contributes to de novo tumour formation and how to interpret autophagy in the context of already established tumours. There is, however, accumulating evidence as outlined above that autophagy is a tumour-suppressive mechanism. Several reports have now provided potential explanations as to how autophagy may function in tumour suppression, including roles in cell death, senescence and the management of metabolic stress.
Autophagy and cell death
The role and mechanisms of autophagy in promoting cell survival in contexts such as nutrient deprivation are unequivocal. It is also without question that autophagy accompanies cell death in certain scenarios, although the exact contribution of autophagy is complex and less well defined. In systems where apoptosis was inhibited, either genetically or pharmacologically, cell death dependent on ATGs was reported (Refs 96, 97); in other words, inhibition of certain ATGs (ATG5, Beclin 1, ATG7) suppressed cell death. In one report, where cells were treated with the caspase inhibitor zVAD-fmk to inhibit caspasedependent death, it was proposed that the cell death was mechanistically driven via the selective autophagic degradation of catalase, which subsequently overloads the cell with damaging ROS (Ref. 98) . A more direct role of ATGs in cell death has also been shown: cleavage of ATG5 has been reported to occur following cell death induction and this cleaved form has a direct proapoptotic role (Ref. 99 ). This could indicate, therefore, that in studies where cell death has been compromised by ATG5 knockdown, incorrect conclusions may have been drawn that the cell death observed was dependent on autophagy. The generality of these observations, however, is yet to be determined.
Clearance of dying cells during salivary gland development in Drosophila melanogaster involves autophagy and in this context it appears that the full-blown cell death response is dependent on caspases and ATGs (Ref. 100). Increasing evidence also suggests a non-cell-autonomous role of autophagy in cell death, which extends the housekeeping functions of autophagy to a multicellular level. In an in vitro mouse model of embryonic development, inhibition of autophagy prevented the upregulation of two important cellsurface engulfment signals -phosphatidylserine and lysophosphatidylcholine -in cells destined to die (Ref. 101) . At first impression, inhibition of autophagy in this system seems to result in cell death, but it is really the energy-dependent expression of engulfment signals that is impeded, which causes the accumulation of cellular corpses by default, that is at play. Exogenous methylpyruvate is an alternative expert reviews http://www.expertreviews.org/ in molecular medicine source of energy and its addition compensates for the low levels of ATP in autophagy-deficient cells, leading to expression of the aforementioned engulfment signals. In an vivo context, it is notable that embryonic Atg5-null mice display reduced phagocytosis of dead cells in lung and retinal tissue, pointing to the wider implications of this phenomenon and to the caution that should be employed when dying cells seemingly arise following autophagy inhibition (Ref. 101) . In all the above-mentioned examples, ATGs facilitate cell death, but it is arguable that a situation has not yet been observed where a cell actually dies solely from autophagy. Furthermore, as discussed above, the role of autophagy in cell death is not restricted to cell-autonomous effects. Therefore, the term 'autophagic cell death' (or programmed cell death type II) has to be used with caution. It has been suggested it be replaced with the term 'cell death with autophagy' as it is now widely considered that autophagy can be a component in cell death, perhaps as a permissive signal, but not its sole perpetrator (Ref. 102 ).
Autophagy in cell cycle arrest, dormancy and senescence
Sustained growth arrest, like programmed cell death, is an important mechanism to counteract tumour growth in vivo and has recently been shown to be critically linked with autophagy (Ref. 100). Senescence is a critical barrier against malignant transformation and an important effector programme of chemotherapy. It is defined as an irreversible cell cycle arrest of viable and metabolically active cells following various endogenous and exogenous stresses (Ref. 103) . In HRAS-V12-infected human diploid fibroblasts, autophagy is activated and its inhibition resulted in delayed onset of the senescent phenotype (Ref. 7) . In a reciprocal fashion, overexpression of the autophagic protein ULK3 induced autophagy and accelerated the onset of senescence (Ref. 7) . However, the exact role of ULK3 in autophagy is currently unclear.
Tumour dormancy generally describes a phase of apparent stasis in tumour growth and is mechanistically subdivided into two models. Single-cell dormancy is a phase of prolonged cell cycle arrest that can be overcome upon cellautonomous genetic changes or alterations in the microenvironment. According to the micrometastasis model, tumour dormancy is a balanced state of cell renewal and cell death (Ref. 104) . (Both dormancy and senescence are not to be confused with quiescence, which is a physiological normal resting state of a cell.) ARHI expression induces autophagy and leads to tumour dormancy in ovarian cancer xenograft models, which can be reversed upon treatment with chloroquine, a pharmacological inhibitor of lysosomal function and therefore autophagy (Ref. 74) .
When taken together, these reports clearly emphasise that growth arrest and autophagy are intertwined, and tentatively posit that autophagy and its role in senescence and dormancy may be a facet of tumour suppression in multiple cancers.
Autophagy and the management of oxidative stress
Metabolic stress, as a result of either insufficient nutrient/oxygen supply or increased energetic demands of rapidly dividing tumour cells, induces autophagy as an alternative source of energy and metabolites. Enhanced autophagy is frequently found in hypoxic regions of tumours and contributes to cell survival (Ref. 105) . Initially, it is therefore illogical how loss of autophagy contributes to tumour formation ( Refs 32, 34, 35) . The first contribution to solve this conundrum came from the observation that metabolic stress promotes necrotic cell death in vivo and in vitro within cells that are defective in both autophagy and apoptosis. Necrotic cell death was associated with a strong inflammatory response, which ultimately enhanced tumour growth (Ref. 105) . This therefore provides one explanation of how autophagy may be tumour suppressivethrough its capacity to impede necrosis. Whether this is a factor, however, downstream of chemotherapeutic drugs that induce cell death through necrosis is an interesting question and worthy of further investigation (Refs 106, 107). Meanwhile it is becoming increasingly substantiated that autophagy reduces oxidative stress, maintains protein and organelle quality control and thereby limits cellular damage (Refs 27, 28) .
Metabolic stress leads to accumulation of ROS, damaged proteins and damaged organelles such as mitochondria (which are in turn additional expert reviews http://www.expertreviews.org/ in molecular medicine sources of ROS) and impedes genetic stability when compensatory mechanisms fail. Autophagy is a critical countermeasure following metabolic insults and attenuates these changes, thereby promoting cellular survival. In different studies, autophagy-defective tumour cells were indeed more susceptible to cell death but, importantly, at the same time were also more susceptible to genomic damage and possessed greatly enhanced tumourigenic potential when compared with autophagycompetent cells in vivo (Refs 27, 28) .
Sequestosome 1 (SQSTM1; p62) has been identified as the critical molecular link between defective autophagy, genomic instability and tumourigenesis (Ref. 26) . p62 is an adapter protein that links polyubiquitinated proteins or aggregates to ATG8/LC3 on the surface of autophagosomes. Importantly, it is also a decisive element in modulating different molecular pathways, such as the nuclear factor NF-kB pathway through recruitment of different signalling molecules and the extrinsic cell death pathway by promoting aggregation of caspase 8 (Ref. 108) . p62 is frequently upregulated in human tumours and of utmost importance in controlling oxidative stress and tumour growth (Refs 26, 109) . Tumour cells, therefore, with impairment in both apoptosis and autophagy preferably accumulate p62 under stress, which thereby promotes tumourigenesis (Ref. 26) . In a self-supporting feedback loop, metabolic stress leads to increased production of ROS that in turn were responsible for accumulation of p62. p62 itself was also causative for further oxidative damage, accumulation of damaged mitochondria, an enhanced induction of the protein-folding machinery in the endoplasmatic reticulum, and a DNA-damage response. Elevated levels of p62 suppressed the activation of target genes of NF-kB. In Ras-induced lung tumours, p62 is essential for tumour formation, but in contrast to the observation by Mathew et al. (Ref. 26) , inhibition of p62 led to impaired NF-kB signalling (Ref. 110 ). These differences in NF-kB activation are not readily explained and may be due to the versatility of p62 in activating different pathways (Ref. 109) or the different cellular contexts. Nonetheless, p62 accumulation is clearly causative for tumourigenesis and exemplifies how cancer progression can be affected by the selective autophagic degradation of a specific protein. Figure 4 illustrates how the metabolic capacity of autophagy might be the decisive factor for proliferation control in tumourigenesis.
Autophagy and therapy -whether to treat and, if so, how?
With regard to the complexity and dichotomy of autophagy in cell death and tumour biology and limited treatment data from in vivo studies, can autophagy be modulated for the benefit of cancer therapy? As a result of the survival effects of autophagy that were initially observed in vitro, the suggestion would have been that autophagy inhibition, in combination with standard chemotherapy, would be beneficial for tumour therapy. When we consider, however, the effects this may have on a necrosis-driven protumour inflammatory response or the effects on impeding cellular senescence, one would perhaps aver that autophagy promotion would be the way to go. Nonetheless, several recent reports have shown that pharmacological inhibition of autophagy with chloroquine might be beneficial for tumour therapy (Refs 74, 111). The effects of chloroquine are, however, not limited to autophagy inhibition, causing, among other things, inhibition of lysosomal function in general, and it is important to note that in vivo genetic verification that the effects of chloroquine in these settings was through modulation of autophagy is yet to be established. In this regard, it is notable that a separate study analysing the therapeutic effectiveness of chloroquine revealed prodeath effects of autophagy. Figure 4 . Autophagy manages cellular stress to counteract tumour growth. In autophagy-competent cells, cellular stress leads either to cell death, growth arrest in the form of premature senescence, or survival. If the autophagic capacity falls below a threshold that is necessary to maintain cell integrity, for example through genetic alterations or pharmaceutical intervention, cells are unable to compensate metabolic stress. As a result, necrotic cell death occurs and causes attraction of tumour-promoting macrophages. In surviving cells, however, failure to clear p62 (sequestosome 1) and p62-associated aggregates results in further accumulation of ROS (reactive oxygen species), damaged proteins and organelles, altered cell signalling and DNA damage. Clinically, this phase might present as an initial tumour remission. However, the acquisition of growth-promoting mutations in a subset of cells might potentially lead to more aggressive tumour cells. Abbreviation: NF-kB, nuclear factor kB. When considering targeting autophagy therapeutically, the effects on normal as well as tumour cells must always be considered. This is no more relevant than with autophagy, which has major homeostatic roles within our normal tissues. For example, the selective ablation of autophagy in the brains of mice has been shown to lead to neurodegenerative disease without any other accompanying mutation, indicating that the systemic modulation of autophagy may be naive (Refs 37, 113). As a result, it seems clear that we perhaps need to understand more about the selective control of autophagy in different settings to enable the bespoke targeting of autophagy to hit diseased cells, but not normal tissue. An understanding of the signalling pathways that talk to the autophagy machinery in response to different forms of cellular stress to bring about different effects may therefore be the key. In this regard, a recent report has identified that signalling from PDGF (platelet-derived growth factor) receptors is a permissive signal for hypoxiadriven autophagy while seemingly having no effects on autophagy driven by other stimuli. Since autocrine PDGFR signalling and hypoxia are both tumour-associated events this may well be a paradigm for the identification of autophagic signalling pathways that could be utilised for targeting tumour-selective autophagy, and further studies of this, and other pathways, undoubtedly merit further investigation (Refs 114, 115; see also Fig. 2) .
In summary, autophagy is important for development and cellular homeostasis, and lies at the intersection of life and death. More and more evidence is accumulating, however, that autophagy is a tumour-suppressive mechanism, with bonds to the control of oxidative damage, cell death and oncogene-induced senescence. Looking at autophagy from a metabolism angle provides explanation of how loss of a cytoprotective mechanism facilitates tumour development through mitigating genomic stress. In line with these desired tumour-suppressive functions, autophagy-enhancing therapy may be as promising a therapeutic strategy as the simple notion of inhibiting autophagy to enhance cell death. It is undoubted, however, that our current understanding of autophagy is incomplete. As more genetic models of autophagy inhibition are developed, which allow the spatial and temporal control of autophagy, this should enable the more effective targeting of autophagy in a both a selective and bespoke manner.
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Note added in proof
The reader should be aware that in the context of autophagy regulation as described in this review, and despite what was previously believed, a recent report has indicated that autophagy can occur in the absence of both ATG5 and ATG7 (Ref. expert reviews http://www.expertreviews.org/ in molecular medicine
